Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.
Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomar
